Enhanced Confidence in Characterization of iPSC-Based Therapeutic Candidates

Current pre-clinical approaches to characterizing iPSC-based therapies may miss significant genomic and transcriptomic heterogeneity. Read our perspective on how emerging single-cell multiomics technologies put more comprehensive data in researchers’ hands.

In this white paper, you'll read about:

  • The genomic and transcriptomic heterogeneity in iPSC culture and reprogramming
  • Why single-cell multiomic analysis is necessary to characterize and validate iPSC-based therapeutic candidates
  • Tools that make it possible to precisely, sensitively detect insertions, deletions, substitutions, larger genomic alterations, alternative splicing events, and altered gene expression across the entire genome – and attribute these variants to individual cells.
Cells Explored. Answers Revealed.
By sharing your email address with us, you agree to receive occasional emails from BioSkryb Genomics, Inc. You can unsubscribe at any time.

Schedule a consultation